Abstract
Numerous in vitro studies have shown that T lymphocytes can be targeted towards any target cell by using bispecific antibodies (bsAbs) with specificity of the CD3/TCR complex and a target cell antigen. We have produced bsAbs directed against the membrane expressed idiotype of the murine B cell lymphomas BCLI and 38C13, and murine CD3 complex. The dual specificity of the hybrid-hybridoma produced monoclonal antibodies (MAbs) could be demonstrated by flow cytometry, the induction of T cell proliferation, the induction of IL2 secretion by polyclonal T cells, and redirected lysis of the relevant target cells. Immunotherapy of tumor bearing animals demonstrated that bsAbs could efficiently target T cells towards the tumor cells, that tumor cell--T cell bridging is established in vivo, and that both T cell subsets contribute to tumor regression resulting in long-term survival and cure of the lymphomas.
| Original language | English |
|---|---|
| Pages | 67-8 |
| Number of pages | 2 |
| Publication status | Published - 1992 |
| Event | third international conference on bispecific antibodies and targeted cellular cytotoxicity - Ostuni, Italy Duration: 13 Jun 1992 → 17 Jun 1992 |
Conference
| Conference | third international conference on bispecific antibodies and targeted cellular cytotoxicity |
|---|---|
| Country/Territory | Italy |
| City | Ostuni |
| Period | 13/06/92 → 17/06/92 |
Keywords
- Animals
- Antibodies
- Antibody-Dependent Cell Cytotoxicity
- cytotoxicity
- Enzyme-Linked Immunosorbent Assay
- immunotherapy
- lymphoma B-cell
- Mice
- Mice, Inbred BALB C
- Mice, Inbred C3H
- T-Lymphocytes
- Tumor Cells, Cultured